Amgen restructures to focus resources on late-stage drugs

10/19/2011 | Los Angeles Times (tiered subscription model)

Amgen said it is eliminating about 380 positions in research and development to focus resources on its late-stage drug pipeline. "It's very expensive to conduct clinical trials," said spokeswoman Mary Klem. "The patient population gets bigger at each phase. That's the crux of what is causing us to make these strategic changes."

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR